Millennium is first industry partner in collaboration to advance personalized medicine for multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) t that it has entered into a multi-year collaboration with USA-based Millennium Pharmaceuticals, the oncology subsidiary of Japan’s largest drugmaker Takeda (TSE: 4502) to advance the MMRF’s emerging research program in personalized medicine. Both organizations believe the MMRF’s Personalized Medicine Initiative program will enable the biological segmentation of patients and accelerate the development of new, targeted treatments and potentially curative approaches for multiple myeloma. Millennium is the first pharmaceutical company to join MMRF in advancing this new initiative.

The MMRF’s Personalized Medicine Initiative is an eight-year, multifaceted program designed to identify the molecular origins of multiple myeloma and enable physicians to match specific treatment approaches to the patients most likely to benefit.

Will enable landmark 1,000-patient CoMMpass longitudinal study to accelerate research